Market research
207940.KO Samsung Biologics Co.,Ltd
KO KRW Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 72T
- P/E ratio
- Not available
- Analyst target
- 999999.9999
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Company facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KR7207940008
- Market cap
- 72T
- P/E ratio
- Not available
- Analyst target
- 999999.9999
- Dividend yield
- Not available
- Beta
- 0.21
About
About Samsung Biologics Co.,Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 207940.KO discussion.
5 years, 4 months ago
Samsung Biologics Co.,Ltd is currently in a long term uptrend where the price is trading 9.4% above its 200 day moving average.
From a valuation standpoint, the stock is 397.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 42.6.
Samsung Biologics Co.,Ltd's total revenue rose by 19.8% to $375B since the same quarter in the previous year.
Its net income has dropped by 54.3% to $96B since the same quarter in the previous year.
Finally, its free cash flow fell by 492.2% to $-217B since the same quarter in the previous year.
Based on the above factors, Samsung Biologics Co.,Ltd gets an overall score of 2/5.